Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers.

Eighteen healthy volunteers received three different formulations of Ginkgo biloba: capsules (A) and drops (B) (delivered by Agon Pharma), and tablets (C) (Tebonin-Dr. W. Schwabe) in equal an quantity, orally as a single dose, at an interval of at least five days. The pharmacokinetic parameters of the most important flavonoid glycosides: quercetin, kaempferol and isorhamnetin were established. The bioavailability was estimated using capsules as a standard formulation. Only the time to reach the peak concentration (tmax) of quercetin, kaempforol and isorhamnetin administered in the form of capsules, was significantly prolonged as compared with drops and tablets. Area under the curve (AUC) was the largest for formulation B for all the evaluated flavonoid glycosides, however the differences were not statistically significant. It is concluded that the three formulations of Ginkgo biloba extract are bioequivalent.

[Comparative evaluation of some morphologic methods for detecting Helicobacter pylori in gastric mucosa]. / Ocena porównawcza niektórych metod morfologicznych wykrywania Helicobacter pylori w blonie sluzowej zoladka.

Gastroscopic examination was performed in 183 patients with upper gastrointestinal symptoms, with brush biopsy and taking of mucosa specimens for cytological and histopathological examination in order to detect the presence of Helicobacter pylori. Greater effectiveness of brush biopsy was demonstrated in comparison to histological examination of tissue fragments and significantly higher effectiveness of staining using the Giemsa-May-Grunwald method was shown in comparison to staining with hematoxylin and eosin.

[Acute intermittent porphyria--diagnostic difficulties and treatment]. / Ostra przerywana porfiria--trudnosci diagnostyczne i leczenie.

A patient is described in whom acute intermittent porphyria was diagnosed after 6 months of treatment and five stays in hospital during which the cause of her manifestations was not established. Treatment of the patient and principles of treatment of acute attack of intermittent porphyria are described.